Wide Ranks

ESLA

Estrella Immunopharma, Inc.

1.04

Top Statistics
Market Cap 37 M Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 24.65 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 4 M Total Cash Per Share 0.1150 Total Debt 4000
Total Debt To Equity 0.0940 Current Ratio 24.65 Book Value Per Share 0.1180
All Measures
Short Ratio 7.00 % Message Board Id finmb_1802952199 Shares Short Prior Month 346197
City EmeryVille Uuid aa42da4c-674b-32a3-bdaa-7ca46edb3082 Previous Close 1.01
First Trade Date Epoch Utc 1 B Book Value 0.1180 Beta 0.2380
Total Debt 4000 Volume 19155 Price To Book 8.81
Fifty Two Week Low 0.6300 Total Cash Per Share 0.1150 Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Net Income To Common -7311723
Short Percent Of Float 0.0006 Implied Shares Outstanding 36 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 19780 Average Volume10days 19780
Total Cash 4 M Next Fiscal Year End 1 B Held Percent Insiders 0.7206
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 1.01 Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.9154 Open 1.01 Free Cashflow -12949376
State CA Dividend Yield 0.00 % Return On Assets -1.22
Time Zone Short Name EST Trailing Eps -0.2400 Day Low 1.00
Address1 5858 Horton Street Shares Outstanding 36 M Price Hint 4
Target High Price 0.0000 Website https://www.estrellabio.com 52 Week Change -0.3735
Average Volume 129829 Recommendation Key none Forward Eps 0.0000
Compensation As Of Epoch Date 1 B Quick Ratio 2305.10 % Is_sp_500 False
Regular Market Day High 1.07 Profit Margins 0.00 % Debt To Equity 0.0940
Fifty Two Week High 3.23 Day High 1.07 Shares Short 6538
Regular Market Open 1.01 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0002 Operating Cashflow -16068306
Currency USD Time Zone Full Name America/New_York Market Cap 37 M
Is_nasdaq_100 False Zip 94608 Quote Type EQUITY
Industry Biotechnology Long Name Estrella Immunopharma, Inc. Regular Market Day Low 1.00
Held Percent Institutions 0.0055 Current Price 1.04 Address2 Suite 370
Financial Currency USD Current Ratio 24.65 Industry Disp Biotechnology
Country United States Float Shares 9 M Two Hundred Day Average 1.09
Enterprise Value 28 M Forward PE 0.0000 Regular Market Volume 19155
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.

The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.

It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.

Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.